Rafael Perfecto Viera
General Practice · Winter Garden, FLNPI 1003205519
Payments from drug & device makers
Across 262 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$896
- Novo Nordisk$639
- AbbVie$476
- Bayer$469
- Lilly USA, LLC$441
- GSK$348
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,207100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$5,207 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 95 | $110,198 |
| TrulicityDulaglutide | 96 | $101,258 |
| JardianceEmpagliflozin | 63 | $84,858 |
| MounjaroTirzepatide | 44 | $62,376 |
| OzempicSemaglutide | 39 | $52,737 |
| EliquisApixaban | 53 | $40,130 |
| RybelsusSemaglutide | 11 | $26,222 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $25,660 |
| KerendiaFinerenone | 30 | $24,936 |
| GemtesaVibegron | 32 | $24,209 |
| EntrestoSacubitril/Valsartan | 13 | $12,927 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $12,312 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,325 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $8,179 |
| CreonLipase/Protease/Amylase | 17 | $8,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $441 | $163,634140 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $896 | $120,523112 claims |
| Boehringer IngelheimJardiance | $157 | $84,85863 claims |
| Novo NordiskOzempic, Rybelsus | $639 | $78,95950 claims |
| PfizerEliquis | $90 | $40,13053 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $348 | $37,97374 claims |
| BayerKerendia | $469 | $24,93630 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $77 | $24,20932 claims |
| NovartisEntresto | $18 | $12,92713 claims |
| AbbVieCreon, Synthroid | $476 | $10,84445 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $1,36811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Winter Garden
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Jorge Monroy AvellaOcoee$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.